Business Strategy and Outlook | 09 Jun 2020
Buoyed by growing demand for radiotherapy (RT), we think Elekta -- as well as its main competitor, Varian -- should enjoy strong sales momentum for the next decade. The RT industry has consolidated substantially over the past decade, and the two companies are in a prime position to benefit from a market we believe will be growing in the midsingle digits.
Although RT is considered a ubiquitous form of cancer treatment, its adoption still has room to increase. RT is highly effective in treating certain cancers at a relatively low cost, but its penetration rates have long been hindered by its side effects and sizable up-front costs. The latest advances in technology, allowing for higher dosage and more precise delivery of radiation, and growing awareness of the benefits of radiotherapy could significantly expand the marketplace.